Matija Veber1, Jan Vogler2, Miomir Knežević3, Ariana Barlič3, Matej Drobnič2,4. 1. Educell Ltd., Prevale 9, 1236, Trzin, Slovenia. matija.veber@educell.si. 2. Department of Orthopedic Surgery, University Medical Centre Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia. 3. Educell Ltd., Prevale 9, 1236, Trzin, Slovenia. 4. Chair of Orthopedics, Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia.
Abstract
BACKGROUND: Osteochondral injury is a very common orthopaedic pathology, mainly affecting young, active population, with limited current treatment options. Herein we are presenting cellular and early clinical data of a patient series treated for chronic osteochondral lesions in the knee with a filter-based intra-operative bone marrow aspirate (BMA) separation device. METHODS: Fifteen patients with chronic knee osteochondral lesions (60% females, 19-59 years) were included in this prospective case series. Filtered BMA (f-BMA), containing mesenchymal stem/stromal cells (MSCs), was combined with a biomimetic collagen-hydroxyapatite scaffold (CHAS) and implanted into the site of the lesion. Harvested BMA and post-separation f-BMA were analysed for blood cell counts, flow cytometry, and fibroblast colony forming units (CFU-Fs). Patients were followed for serious adverse events and graft failures. Clinical evaluation was assessed using the knee injury and osteoarthritis outcome score (KOOS). In 8 patients a magnetic resonance imaging (MRI)/arthroscopy were performed. RESULTS: Cell suspension contained 0.027% CD271+ CD45- 7-AAD- cells, 0.15% CD73+ CD90+ CD105+ cells and 0.0012% CFU-Fs of all nucleated cells with 86% viability. Filtration process resulted in 12.8 (4.0-40.8) fold enrichment in terms of CFU-F content in comparison to initial BMA. No serious adverse events related directly to the osteochondral treatment were reported. After an average follow-up of 20 months (14-25) all KOOS subscales (Symptoms/Pain/Daily activities/Sport and recreation/Quality of life) increased significantly from pre-operative 55/56/67/30/30 to post-operative 73/76/79/51/52 (p values < 0.05), respectively. MRI or arthroscopic evaluation revealed nearly normal to normal overall International Cartilage Repair Society assessment in 7/8 patients. CONCLUSION: The filter-based BMA separation procedure significantly increased the frequency of mesenchymal stem/stromal cells (MSCs), however their concentration was not increased. The clinical evaluation revealed high safety profile of the treatment and resulted in improved clinical status of the patients.
BACKGROUND:Osteochondral injury is a very common orthopaedic pathology, mainly affecting young, active population, with limited current treatment options. Herein we are presenting cellular and early clinical data of a patient series treated for chronic osteochondral lesions in the knee with a filter-based intra-operative bone marrow aspirate (BMA) separation device. METHODS: Fifteen patients with chronic knee osteochondral lesions (60% females, 19-59 years) were included in this prospective case series. Filtered BMA (f-BMA), containing mesenchymal stem/stromal cells (MSCs), was combined with a biomimetic collagen-hydroxyapatite scaffold (CHAS) and implanted into the site of the lesion. Harvested BMA and post-separation f-BMA were analysed for blood cell counts, flow cytometry, and fibroblast colony forming units (CFU-Fs). Patients were followed for serious adverse events and graft failures. Clinical evaluation was assessed using the knee injury and osteoarthritis outcome score (KOOS). In 8 patients a magnetic resonance imaging (MRI)/arthroscopy were performed. RESULTS: Cell suspension contained 0.027% CD271+ CD45- 7-AAD- cells, 0.15% CD73+ CD90+ CD105+ cells and 0.0012% CFU-Fs of all nucleated cells with 86% viability. Filtration process resulted in 12.8 (4.0-40.8) fold enrichment in terms of CFU-F content in comparison to initial BMA. No serious adverse events related directly to the osteochondral treatment were reported. After an average follow-up of 20 months (14-25) all KOOS subscales (Symptoms/Pain/Daily activities/Sport and recreation/Quality of life) increased significantly from pre-operative 55/56/67/30/30 to post-operative 73/76/79/51/52 (p values < 0.05), respectively. MRI or arthroscopic evaluation revealed nearly normal to normal overall International Cartilage Repair Society assessment in 7/8 patients. CONCLUSION: The filter-based BMA separation procedure significantly increased the frequency of mesenchymal stem/stromal cells (MSCs), however their concentration was not increased. The clinical evaluation revealed high safety profile of the treatment and resulted in improved clinical status of the patients.
Authors: Richard Cuthbert; Sally A Boxall; Hiang Boon Tan; Peter V Giannoudis; Dennis McGonagle; Elena Jones Journal: Cytotherapy Date: 2012-01-24 Impact factor: 5.414
Authors: M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz Journal: Cytotherapy Date: 2006 Impact factor: 5.414
Authors: Jonathan I Dawson; James O Smith; Alexander Aarvold; Jonathan N Ridgway; Steven J Curran; Douglas G Dunlop; Richard O C Oreffo Journal: Cytotherapy Date: 2012-12-12 Impact factor: 5.414
Authors: M Marcacci; S Zaffagnini; E Kon; G M Marcheggiani Muccioli; A Di Martino; B Di Matteo; T Bonanzinga; F Iacono; G Filardo Journal: Knee Surg Sports Traumatol Arthrosc Date: 2013-01-31 Impact factor: 4.342
Authors: David Martinčič; Jure Leban; Giuseppe Filardo; Maurizio Busacca; Ariana Barlič; Matija Veber; Matej Drobnič Journal: Int Orthop Date: 2020-07-25 Impact factor: 3.075
Authors: Christoph Schmitz; Christopher Alt; David A Pearce; John P Furia; Nicola Maffulli; Eckhard U Alt Journal: Cells Date: 2022-03-11 Impact factor: 6.600